Abstract
Since the development of antibody phage display, 20 years ago, this technique has been evolved to a valuable and robust tool for the development of recombinant human antibodies. Today, this technique is widely used for the generation of antibodies for therapy and basic research. Automation processes and decrease of costs will enable the highthroughput design of monoclonal binders against a huge number of different antigens, presenting a valuable tool for proteome research. This review presents an overview on phage display technology and antibody libraries. The benefit of recombinant antibodies for basic research, diagnostic and therapy is shown.
Keywords: phage display, scFv, antibody, proteome research, antibody gene library, monoclonal antibody, human antibody, Humira, antibody genes, Murine antibodies, B-lymphocytes from, IgGs, E. coli, phagemid, bacteriophage M13
Current Biotechnology
Title: Generating Recombinant Antibodies for Research, Diagnostics and Therapy Using Phage Display
Volume: 1 Issue: 1
Author(s): Andre Frenzel, David Frode, Torsten Meyer, Thomas Schirrmann and Michael Hust
Affiliation:
Keywords: phage display, scFv, antibody, proteome research, antibody gene library, monoclonal antibody, human antibody, Humira, antibody genes, Murine antibodies, B-lymphocytes from, IgGs, E. coli, phagemid, bacteriophage M13
Abstract: Since the development of antibody phage display, 20 years ago, this technique has been evolved to a valuable and robust tool for the development of recombinant human antibodies. Today, this technique is widely used for the generation of antibodies for therapy and basic research. Automation processes and decrease of costs will enable the highthroughput design of monoclonal binders against a huge number of different antigens, presenting a valuable tool for proteome research. This review presents an overview on phage display technology and antibody libraries. The benefit of recombinant antibodies for basic research, diagnostic and therapy is shown.
Export Options
About this article
Cite this article as:
Frenzel Andre, Frode David, Meyer Torsten, Schirrmann Thomas and Hust Michael, Generating Recombinant Antibodies for Research, Diagnostics and Therapy Using Phage Display, Current Biotechnology 2012; 1 (1) . https://dx.doi.org/10.2174/2211550111201010033
DOI https://dx.doi.org/10.2174/2211550111201010033 |
Print ISSN 2211-5501 |
Publisher Name Bentham Science Publisher |
Online ISSN 2211-551X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Management and Treatment of Dengue and Chikungunya - Natural Products to the Rescue
Combinatorial Chemistry & High Throughput Screening Antiviral Marine Natural Products
Current Medicinal Chemistry - Anti-Infective Agents Molecular Imaging with Small Animal PET/CT
Current Medical Imaging Neurodegeneration with Dementia: From Fundamentals of Pathology to Clinical Imaging by MRI and SPECT.
Current Medical Imaging Mitochondrial Dysfunction in Huntington’s Disease: Pathogenesis and Therapeutic Opportunities
Current Drug Targets Regenerative Medicine: Does Erythropoietin have a Role?
Current Pharmaceutical Design Pharmacological Targeting of IDO-Mediated Tolerance for Treating Autoimmune Disease
Current Drug Metabolism Abscisic Acid, a Plant Hormone, Could be a Promising Candidate as an Anti-Japanese Encephalitis Virus (JEV) Agent
Anti-Infective Agents Targeting TNF-Alpha to Elucidate and Ameliorate Neuroinflammation in Neurodegenerative Diseases
CNS & Neurological Disorders - Drug Targets Drug Targets from Genetics: Alpha-Synuclein
CNS & Neurological Disorders - Drug Targets Antiviral Activity of Jodantipyrin – An Anti-Inflammatory Oral Therapeutic with Interferon-Inducing Properties
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Targeting STEAP1 Protein in Human Cancer: Current Trends and Future Challenges
Current Cancer Drug Targets Using Biologic Agents in Pediatric Rheumatologic Diseases
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Regulation of Protective and Pathogenic Th17 Responses
Current Immunology Reviews (Discontinued) Current and Future Prospective of a Versatile Moiety: Imidazole
Current Drug Targets New Approaches to Chikungunya Virus Vaccine Development
Recent Patents on Inflammation & Allergy Drug Discovery The Yin and Yang of Antiviral Innate Immunity in Central Nervous System
Current Pharmaceutical Design Synthesis and Antiviral Activity of Dihydropyrimidines - Ciprofloxacin Mannich bases Against Various Viral Strains
Anti-Infective Agents Innate Immunity in Alzheimer’s Disease: A Complex Affair
CNS & Neurological Disorders - Drug Targets A V<sub>L</sub>-linker-V<sub>H</sub> orientation dependent single chain variable antibody fragment against rabies virus G protein with enhanced neutralizing potency in vivo.
Protein & Peptide Letters